

IIIM-284

[IIIM-284/14 (Target: PI3K-alpha)]

It is a new analog of a clinical candidate (ZSTK474), possessing potent inhibition of PI3Ks (IC₅₀ value 23-115 nM). It possess potent in-vitro cytotoxicity in MCF-7 cell line. Is has excellent oral pharmacokinetics profile (PK in BALB/c mice at 10 mg/kg (p.o.): t_{1/2,β} = 8.99 h; AUC_{0-t} = 4350 ng•h/mL; C_{max} = 430 ng/mL; Oral bioavailability = 47%). It showed promising in-vivo efficacy in murine solid tumor model by oral route. This lead is presently under in-vivo validation in human xenograft models.